What You Should Know:
– Scopio Labs, developer of Full-Field Cell Morphology imaging and analysis platform, announced today the unveiling of its groundbreaking Complete Blood Morphology (CBM®) analyzer. CBM will bring unprecedented scale, efficiency and standardization to hematology through autonomous morphology analysis and reporting, one of the last remaining manual processes in diagnostics.
– To expedite the go-to-market of CBM®, Viola Growth has joined as a new investor with a $10 million extension to Scopio’s Series D funding, bringing the total to $52 million.
Closing the Automation Gap in Hematology with CBM® and Scopio’s Full-Field Technology
Addressing a Critical Bottleneck in Peripheral Blood Smear Review
Despite decades of automation in Complete Blood Count (CBC) testing, the peripheral blood smear (PBS) review process remains labor-intensive, inconsistent, and a significant bottleneck in clinical workflows. This challenge is compounded by global workforce shortages, long technologist training cycles, and rising diagnostic demand—all contributing to delayed turnaround times and compromised scalability in patient care. While automation has streamlined many areas of the lab, PBS review still relies on human interpretation, introducing variability and inefficiency that modern laboratories can no longer afford.
Scopio Labs’ CBM®: A New Era of Automated Morphology
Scopio Labs’ CBM® platform, powered by its proprietary Full-Field imaging technology and AI-driven analysis, is designed to autonomously process PBS reviews, analyzing 10x more cells than traditional methods. The result is a standardized, scalable, and clinically robust workflow that reduces dependency on manual review. Laboratories already using Scopio’s CE-marked and FDA-cleared digital platforms for PBS and bone marrow aspirate analysis are seeing marked improvements in efficiency and readiness for CBM® integration.
According to Itai Hayut, CEO and Co-founder of Scopio Labs, “Our vision is to be the first to close the automation gap in hematology by developing a fully integrated and automated hematology process from CBC to final result. This isn’t just a small step forward—it’s a paradigm shift that could redefine hematology workflows and economics.” Beyond automating current practices, CBM® is also positioned to unlock new capabilities in morphology-based biomarkers and diagnostic panels, facilitating early disease detection and monitoring directly from blood samples.
